



L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS  
 AN 2001:208277 CAPLUS  
 DN 134:237495  
 TI Preparation of heteroaromatic amines as protein kinase inhibitors  
 IN Hirst, Gavin C.  
 PA BASF A.-G., Germany  
 SO PCT Int. Appl., 140 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WC 2001019828	A2	20010322	WO 2000-US25357	20000915
	WC 2001019828	A3	20011004		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-154618	P	19990917		
OS	MP: PAT 134:237495				
GI					




AB Two title compd., e.g., I, were prepd. as protein kinase inhibitors (no data). Thus, NCCH<sub>2</sub>NHC<sub>6</sub>H<sub>4</sub>(OPh)-4 was cyclocondensed with .alpha.-formylcyclopentaneacetonitrile (prepn. each given) and the product cyclocondensed with HC(:NH)NH<sub>2</sub>.HOAc to give I.  
 IT **330666-31-4P**  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of heteroarom. amines as protein kinase inhibitors)  
 RN 330666-31-4 CAPLUS  
 CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclopentyl-5-(4-phenoxyphenyl)-(9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS  
 AN 1998:42401 CAPLUS  
 DN 128:102099  
 TI Substituted 7-aminopyrrolo[3,2-d]pyrimidines and their use as inhibitors of tyrosine protein kinase pp60c-src  
 IN Altmann, Eva; Missbach, Martin; Widler, Leo; Maibaum, Jurgen Klaus  
 PA Novartis A.-G., Switz.; Altmann, Eva; Missbach, Martin; Widler, Leo; Maibaum, Jurgen Klaus  
 SO PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9749706	A1	19971231	WO 1997-EP3115	19970616
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9731762	A1	19980114	AU 1997-31762	19970616
PRAI	CH 1996-1591		19960625		
	WO 1997-EP3115		19970616		
OS	MARPAT 128:102099				
GI					




AB Pyrrolo[3,2-d]pyrimidines I [R1, R3 = (un)substituted or hetero-substituted alkyl, cyclohydrocarbyl, aryl, arylalkyl, heterocyclyl, or heterocyclylalkyl; R2 = H, alkyl, halo] and salts are described. The compds. have valuable pharmaceutical properties, and are effective esp. as tyrosine protein kinase inhibitors. They can be used in warm-blooded animals in the treatment of bone diseases and other diseases that are favorably influenced by inhibition of tyrosine protein kinase. Over 100 compds. were prepd. and/or claimed. For instance, Et 3-amino-4-phenyl-1H-pyrrole-2-carboxylate (prepn. given) underwent N-(dimethylamino)methylenation, cyclocondensation with NH3 to give a pyrrolopyrimidinone, conversion of oxo to chloro, N-alkylation with iso-PrBr, and ammonolysis of the chloride, to give title compd. I [R1 = iso-Pr, R2 = H, R3 = Ph]. At concns. of 0.001-10 .mu.M in vitro, I inhibited tyrosine protein kinase pp60c-src. I also gave partial to complete inhibition of bone loss, when administered in the Hock model (ovariectomized rat) at 1-100 mg/kg/day orally.

IT **201465-60-3P 201465-61-4P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (intermediate; prepn. of substituted aminopyrrolopyrimidines as tyrosine protein kinase inhibitors)


RN 201465-60-3 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-iodoethoxy)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201465-61-4 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-chloroethoxy)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



IT 201464-34-8P 201464-85-9P 201464-86-0P


201464-87-1P 201464-88-2P 201464-89-3P

201464-93-9P 201464-95-1P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of substituted aminopyrrolopyrimidines as tyrosine protein kinase inhibitors)


RN 201464-34-8 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclohexen-1-yl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 201464-85-9 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclopenten-1-yl)-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 201464-86-0 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclopenten-1-yl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 201464-87-1 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclopenten-1-yl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 201464-88-2 CAPLUS

CN Phenol, 3-[4-amino-7-(1-cyclopenten-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201464-89-3 CAPLUS

CN Phenol, 4-[4-amino-7-(1-cyclopenten-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201464-93-9 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 201464-95-1 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-cyclopenten-1-yl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




IT 201464-25-7P 201464-27-9P 201464-28-0P  
 201464-29-1P 201464-30-4P 201464-31-5P  
 201464-32-6P 201464-33-7P 201464-35-9P  
 201464-36-0P 201464-37-1P 201464-38-2P  
 201464-39-3P 201464-40-6P 201464-41-7P  
 201464-42-8P 201464-43-9P 201464-44-0P  
 201464-45-1P 201464-46-2P 201464-47-3P  
 201464-48-4P 201464-49-5P 201464-50-8P  
 201464-51-9P 201464-52-0P 201464-53-1P  
 201464-54-2P 201464-55-3P 201464-56-4P  
 201464-57-5P 201464-58-6P 201464-59-7P  
 201464-60-0P 201464-61-1P 201464-62-2P  
 201464-63-3P 201464-64-4P 201464-65-5P  
 201464-66-6P 201464-67-7P 201464-68-8P  
 201464-69-9P 201464-70-2P 201464-71-3P  
 201464-72-4P 201464-73-5P 201464-74-6P  
 201464-75-7P 201464-76-8P 201464-77-9P  
 201464-79-1P 201464-80-4P 201464-81-5P  
 201464-82-6P 201464-83-7P 201464-84-8P  
 201464-90-6P 201464-91-7P 201464-92-8P  
 201464-94-0P 201464-96-2P 201464-97-3P  
 201464-98-4P 201464-99-5P 201465-00-1P  
 201465-01-2P 201465-02-3P 201465-03-4P  
 201465-04-5P 201465-05-6P 201465-06-7P  
 201465-07-8P 201465-08-9P 201465-09-0P  
 201465-10-3P 201465-11-4P 201465-12-5P  
 201465-13-6P 201465-14-7P 201465-15-8P  
 201465-16-9P 201465-17-0P 201465-18-1P  
 201465-19-2P 201465-20-5P 201465-21-6P  
 201465-22-7P 201465-23-8P 201465-24-9P  
 201465-25-0P

RL: BAC (Biological activity or effector, except adverse); SPN  
 (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); USES (Uses)

(prepn. of substituted aminopyrrolopyrimidines as tyrosine protein kinase inhibitors)


RN 201464-25-7 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5,7-diphenyl- (9CI) (CA INDEX NAME)




RN 201464-27-9 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(4-methoxyphenyl)-7-phenyl- (9CI)  
(CA INDEX NAME)




RN 201464-28-0 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-phenyl- (9CI)  
(CA INDEX NAME)




RN 201464-29-1 CAPLUS

CN Phenol, 4-(4-amino-7-phenyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI) (CA INDEX NAME)




RN 201464-30-4 CAPLUS

CN Phenol, 3-(4-amino-7-phenyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI) (CA INDEX NAME)




RN 201464-31-5 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-[4-[2-(phenylmethoxy)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 201464-32-6 CAPLUS

CN Ethanol, 2-[4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenoxy]- (9CI) (CA INDEX NAME)



RN 201464-33-7 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 201464-35-9 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclohexyl-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 201464-36-0 CAPLUS

CN Phenol, 3-[4-amino-7-(1-cyclohexen-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]-  
(9CI) (CA INDEX NAME)




RN 201464-37-1 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(3-pyridinyl)- (9CI) (CA  
INDEX NAME)



RN 201464-38-2 CAPLUS


CN Phenol, 4-[4-amino-7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201464-39-3 CAPLUS


CN Phenol, 3-[4-amino-7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)

d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201464-40-6 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 201464-41-7 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201464-42-8 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-aminoethoxy)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 201464-43-9 CAPLUS


CN Phenol, 4-[4-amino-7-[4-(2-aminoethoxy)phenyl]-5H-pyrrolo[3,2-d]pyrimidin-

5-yl]- (9CI) (CA INDEX NAME)




RN 201464-44-0 CAPLUS

CN Phenol, 3-[4-amino-7-[4-(2-aminoethoxy)phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201464-45-1 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-aminoethoxy)phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 201464-46-2 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-aminoethoxy)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 201464-47-3 CAPLUS

CN Ethanol, 2-[[2-[4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 201464-48-4 CAPLUS

CN Phenol, 4-[4-amino-7-[4-[2-[(2-hydroxyethyl)amino]ethoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201464-49-5 CAPLUS


CN Phenol, 3-[4-amino-7-[4-[2-[(2-hydroxyethyl)amino]ethoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201464-50-8 CAPLUS  
 CN Ethanol, 2-[[2-[4-[4-amino-5-(4-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 201464-51-9 CAPLUS  
 CN Ethanol, 2-[[2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 201464-52-0 CAPLUS  
 CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclohexen-1-yl)-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 201464-53-1 CAPLUS  
 CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclopentyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 201464-54-2 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-cyclopenten-1-yl)-5-phenyl-  
(9CI)


(CA INDEX NAME)



RN 201464-55-3 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-cyclopenten-1-yl)-5-phenyl-  
(9CI)


(CA INDEX NAME)



RN 201464-56-4 CAPLUS

CN Cyclopentanol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-  
(9CI)


(CA INDEX NAME)



RN 201464-57-5 CAPLUS


CN 2-Cyclopenten-1-ol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-  
(9CI)

(CA INDEX NAME)




RN 201464-58-6 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-methoxycyclopentyl)-5-phenyl-  
(9CI) (CA INDEX NAME)




RN 201464-59-7 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-methoxy-1-cyclopenten-1-yl)-5-  
phenyl- (9CI) (CA INDEX NAME)




RN 201464-60-0 CAPLUS

CN Cyclopentanemethanol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-  
yl)-  
(9CI) (CA INDEX NAME)



RN 201464-61-1 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[3-(methoxymethyl)cyclopentyl]-5-  
phenyl- (9CI) (CA INDEX NAME)



RN 201464-62-2 CAPLUS

CN 1,2-Cyclopentanediol, 4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-


(9CI) (CA INDEX NAME)



RN 201464-63-3 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-fluorocyclopentyl)-5-phenyl-


(9CI) (CA INDEX NAME)



RN 201464-64-4 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3,4-difluorocyclopentyl)-5-phenyl-


(9CI) (CA INDEX NAME)



RN 201464-65-5 CAPLUS

CN Cyclohexanol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-


(9CI) (CA INDEX NAME)



RN 201464-66-6 CAPLUS




CN 2-Cyclohexen-1-ol, 3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-  
(9CI) (CA INDEX NAME)




RN 201464-67-7 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(3-methoxycyclohexyl)-5-phenyl-  
(9CI) (CA INDEX NAME)




RN 201464-68-8 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[3-(methoxymethyl)cyclohexyl]-5-phenyl-  
(9CI) (CA INDEX NAME)




RN 201464-69-9 CAPLUS

CN Cyclohexanol, 4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-  
(9CI)  
(CA INDEX NAME)




RN 201464-70-2 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(4-methoxycyclohexyl)-5-phenyl-  
(9CI) (CA INDEX NAME)




RN 201464-71-3 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(methoxymethyl)cyclohexyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 201464-72-4 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(3-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 201464-73-5 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-methyl-3-piperidinyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 201464-74-6 CAPLUS


CN Pyrrolidine, 1-acetyl-3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)- (9CI) (CA INDEX NAME)




RN 201464-75-7 CAPLUS  
 CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(3-piperidinyl)- (9CI)  
 (CA INDEX NAME)




RN 201464-76-8 CAPLUS  
 CN Piperidine, 1-acetyl-3-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-  
 (9CI) (CA INDEX NAME)



RN 201464-77-9 CAPLUS  
 CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(4-piperidinyl)- (9CI)  
 (CA INDEX NAME)




RN 201464-79-1 CAPLUS  
 CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-(1-methyl-4-piperidinyl)-5-phenyl-  
 (9CI) (CA INDEX NAME)




RN 201464-80-4 CAPLUS  
 CN Piperidine, 1-acetyl-4-(4-amino-5-phenyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-  
 (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)




RN 201464-81-5 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[5-(methoxymethyl)-3-pyrrolidinyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 201464-82-6 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(tetrahydro-3-furanyl)- (9CI) (CA INDEX NAME)




RN 201464-83-7 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(tetrahydro-3-thienyl)- (9CI) (CA INDEX NAME)




RN 201464-84-8 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-phenyl-7-(tetrahydro-1,1-dioxido-3-thienyl)- (9CI) (CA INDEX NAME)




RN 201464-90-6 CAPLUS

CN Phenol, 4-(4-amino-7-cyclopentyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI)  
(CA INDEX NAME)




RN 201464-91-7 CAPLUS

CN Phenol, 3-(4-amino-7-cyclopentyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI)  
(CA INDEX NAME)




RN 201464-92-8 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclopentyl-5-(3-fluorophenyl)-  
(9CI) (CA INDEX NAME)




RN 201464-94-0 CAPLUS

CN Phenol, 3-[4-amino-7-(1-methylethyl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]-  
(9CI) (CA INDEX NAME)




RN 201464-96-2 CAPLUS

CN Phenol, 3-[4-amino-7-(3-cyclopenten-1-yl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]-  
(9CI) (CA INDEX NAME)




RN 201464-97-3 CAPLUS

CN Phenol, 3-(4-amino-7-cyclohexyl-5H-pyrrolo[3,2-d]pyrimidin-5-yl)- (9CI)  
(CA INDEX NAME)



RN 201464-98-4 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-cyclopentyl-5-(3-methoxyphenyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 201464-99-5 CAPLUS

CN Ethanol, 2-[[2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]methylamino]- (9CI) (CA INDEX NAME)




RN 201465-00-1 CAPLUS

CN Ethanol, 2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]- (9CI) (CA INDEX NAME)




RN 201465-01-2 CAPLUS

CN Phenol, 3-[4-amino-7-[4-(2-hydroxyethoxy)phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 201465-02-3 CAPLUS


CN Ethanol, 2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 201465-03-4 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201465-04-5 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 201465-05-6 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-[[4-(fluorophenyl)methyl]amino]ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)






RN 201465-06-7 CAPLUS

CN Cyclohexanol, 4-[[2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 201465-07-8 CAPLUS


CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-[4-[2-(1-piperazinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 201465-08-9 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-[2-(dimethylamino)ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 201465-09-0 CAPLUS

CN 3-Pyrrolidinol, 1-[2-[4-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 201465-10-3 CAPLUS


CN Ethanol, 2-[4-[4-amino-5-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 201465-11-4 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[4-(2-aminoethoxy)phenyl]-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)





RN 201465-12-5 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[4-[2-[(2-methoxyethyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)





RN 201465-13-6 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[4-[2-[(2-methoxyethyl)methylamino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 201465-14-7 CAPLUS

CN Ethanol, 2-[2-[4-[4-amino-5-(3-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 201465-15-8 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 201465-16-9 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[4-[2-(1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 201465-17-0 CAPLUS

CN Phenol, 3-[4-amino-7-(4-hydroxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201465-18-1 CAPLUS

CN Phenol, 3-[4-amino-7-[4-[2-[(2-hydroxyethyl)methylamino]ethoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201465-19-2 CAPLUS

CN Phenol, 3-[4-amino-7-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5H-pyrrolo[3,2-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 201465-20-5 CAPLUS

CN 3-Pyrrolidinol, 1-[2-[4-[4-amino-5-(3-hydroxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 201465-21-6 CAPLUS


CN Ethanol, 2-[3-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 201465-22-7 CAPLUS

CN Ethanol, 2-[[2-[3-[4-amino-5-(3-methoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl]phenoxy]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 201465-23-8 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 201465-24-9 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 7-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 201465-25-0 CAPLUS

CN 5H-Pyrrolo[3,2-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-[3-[2-(1-piperazinyl)ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L13 ANSWER 1 OF 4 MARPAT COPYRIGHT 2001 ACS

AN 127:108841 MARPAT

TI Preparation of heterocyclcyl compounds as drugs

IN Saito, Tsuneo; Takahashi, Toshiya; Kawabe, Norio; Moriya, Yoshiko;  
Tanaka, Toshiaki

PA Toray Industries, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 12 pp.


CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 09176116	A2	19970708	JP 1995-340181	19951227
GI					



AB The title compds. (I; A, B, C, D, X = N, C; when X = N, Y = N, C; when X = C, Y = H, C1-4 alkyl, aryl, S, O, etc.; R1 = H, NH2, C1-4 alkyl, OH, etc.; R2-R4 = H, OH, NH2, etc.) are prepd. I are useful as inflammation, allergy, and arthritis inhibitors. Thus, benzo[b]thiophene was reacted with 3,4-dimethoxybenzyl chloride in the presence of zinc chloride and then treated with HBr to give I (A = B = C = D = X = C, Y = S, R1 = R4 = H, R2 = R3 = OH) (II). II showed inhibitory activity for ICAM-1, VCAM-1, IL-1.beta., and 25.8% inhibitory activity for ear edema when tested with mouse.

#### MSTR 1



G1 = N / 9

G2

G2 = NH2

G4 = 21-22 19-4 21-5

G6-CH=CH

G6 = 29

G7

G7 = Ph


DER: and pharmacologically acceptable salts

MPL: claim 1


NTE: substitution is restricted

L13 ANSWER 2 OF 4 MARPAT COPYRIGHT 2001 ACS  
 AN 122:105862 MARPAT  
 TI Preparation and formulation of azaindoles as ulcer inhibitors  
 IN Takahashi, Toshihiro; Horigome, Masato; Momose, Kenichi; Nagai, Shinji;  
 Oshida, Norio; Sugita, Masanori; Katsuyama, Koichi; Suzuki, Chikako;  
 Nakamaru, Koichi  
 PA Nisshin Flour Milling Co, Japan  
 SO Jpn. Kokai Tokkyo Koho, 18 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 06247967	A2	19940906	JP 1993-35268	19930224
GI					




I




II

AB The title compds. I [R1 = aryl, etc.; R2 = H; R3 = H, alkyl, etc.; R4 = H, alkyl, alkoxy, etc.; R5 = H, alkoxy, etc.; X, Y, Z = N, C; provisos are given] are prepd. Azaindole deriv. II (prepn. given) in vitro at 10 .mu.g/mL gave 96.2% inhibition of H+, K+-ATPase.

#### MSTR 1



G4 = pyridyl (SR alkoxy carbonyl<(1-4)>)  
 G7 = NH2  
 G9 = 50-2 52-35




G11 = N  
 DER: and pharmacologically acceptable acid addition salts  
 MPL: claim 1  
 NTE: substitution is restricted




L13 ANSWER 3 OF 4 MARPAT COPYRIGHT 2001 ACS  
 AN 119:226417 MARPAT  
 TI Preparation of condensed pyrimidinylacetyl amino acids as neoplasm inhibitors  
 IN Akimoto, Hiroshi; Ootsu, Koichiro; Itoh, Fumio  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Eur. Pat. Appl., 51 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 530537	A1	19930310	EP 1992-113523	19920807
	EP 530537	B1	19970108		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5403843	A	19950404	US 1992-926170	19920807
	AT 147386	E	19970115	AT 1992-113523	19920807
	CA 2075787	AA	19930213	CA 1992-2075787	19920811
	JP 06049069	A2	19940222	JP 1992-214142	19920811
PRAI	JP 1991-202042		19910812		
	JP 1992-71513		19920327		
	JP 1992-145851		19920605		
GI	For diagram(s), see printed CA Issue.				
AB	Title compds. [I; ring A = (substituted) (hydrogenated) 5-membered ring;				
B	= (substituted) divalent 5- or 6-membered homo- or heterocyclic group; X				
=	amino, OH, SH; Y = H, halo, C-, N-, O-, or S-bonded group; Z =				
	(substituted) (heteroatom-contg.) divalent group having .ltoreq.5 atoms;				
W	= NRCO; R = H, (substituted) alkyl; R1 = (substituted) cyclic or				
	chain-like group; or RR1 = atoms to form a 3-13 membered ring CO2R2 =				
	optionally esterified carboxyl group; p = 1-4; with provisos], were				
prepd.	Thus, N.alpha.-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-				
	yl)ethyl]benzoyl]-N.delta.-phthaloyl-L-ornithine Me ester [prepd. by				
L-	condensation of the corresponding benzoic acid with N.delta.-phthaloyl-				
	ornithine Me ester.HCl using di-Et cyanophosphate and Et3N in DMF] was				
sapon-	sapon. to give N.alpha.-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-				
5-	yl)ethyl]benzoyl]-N.delta.-hemipthaloyl-L-ornithine. This inhibited				
	proliferation of A549 cells with IC50 = 0.0012 .mu.g/mL.				


# MSTR 1B



G1 = 22-2 20-1 22-10




G2 = Ph (SO (1-3) G3)  
 G6 = 55




G11 = NH2  
 DER: or salts  
 MPL: claim 1  
 NTE: substitution is restricted


# **MSTR 2B**



G1 = 22-2 20-1 22-10




G2 = Ph (SO (1-3) G3)  
 G6 = 55



G11 = NH2  
 DER: or salt reactive derivatives  
 MPL: claim 72


L13 ANSWER 4 OF 4 MARPAT COPYRIGHT 2001 ACS  
 AN 118:147575 MARPAT  
 TI Preparation of (arenopyrimidinylthio)acetates and analogs  
 IN Gewald, Karl; Schaefer, Harry; Jeschke, Torsten; Eckert, Katrin; Faust, Gottfried; Laban, Gunter  
 PA Arzneimittelwerk Dresden GmbH, Germany  
 SO Ger. Offen., 7 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4119767	A1	19921217	DE 1991-4119767	19910615
OS	CASREACT 118:147575				
GI					




AB Title compds. [I; A = atoms to complete a (substituted) arom. or heterocyclic ring; R1 = NH2, OH; R2 = OH, alkoxy; X = Se, S; dashed lined = optional bond] were prepd. by cyclocondensation of acetamidocyclic compds. II (R = halo, Y = cyano, alkoxycarbonyl) with SCN- or SeCN- in the presence of R2H. Thus, 2-(NC)C6H4NHCOCH2Cl was refluxed 3 h with KSCN in EtOH to give 69% title compd. III.

#### MSTR 1H




G1 = NH2  
 G6 = 111-6 112-3 113-136




G10 = Ph (SO (1-) G9)  
 MPL: claim 1

=> d l1; d l5; d his  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L5 HAS NO ANSWERS  
L5 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'MARPAT' ENTERED AT 13:36:59 ON 08 NOV 2001)  
DEL HIS

FILE 'STNGUIDE' ENTERED AT 13:38:30 ON 08 NOV 2001

FILE 'REGISTRY' ENTERED AT 13:44:45 ON 08 NOV 2001

L1 STRUCTURE UPLOADED  
L2 25 S L1  
L3 502 S L1 FUL

FILE 'CAPLUS' ENTERED AT 13:45:40 ON 08 NOV 2001

L4 99 S L3

FILE 'REGISTRY' ENTERED AT 13:54:57 ON 08 NOV 2001

L5 STRUCTURE UPLOADED  
L6 4 S L5 SAM SUB=L3  
L7 106 S L5 FUL SUB=L3

FILE 'CAPLUS' ENTERED AT 13:55:31 ON 08 NOV 2001

L8 2 S L7

FILE 'BEILSTEIN' ENTERED AT 13:56:50 ON 08 NOV 2001

L9 0 S L5  
L10 0 S L5 FUL

FILE 'MARPAT' ENTERED AT 13:57:17 ON 08 NOV 2001

L11 0 S L5  
L12 6 S L5 FUL  
L13 4 S L12 NOT L8

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

109.86

932.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE


-2.24

-61.63

STN INTERNATIONAL LOGOFF AT 13:58:28 ON 08 NOV 2001

09/663,320

=> d l1; d his  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 13:35:42 ON 08 NOV 2001)

FILE 'REGISTRY' ENTERED AT 13:35:51 ON 08 NOV 2001

L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 0 S L1 FUL

FILE 'BEILSTEIN' ENTERED AT 13:36:34 ON 08 NOV 2001

L4 0 S L1  
L5 0 S L1 FUL

FILE 'MARPAT' ENTERED AT 13:36:59 ON 08 NOV 2001

L6 0 S L1  
L7 0 S L1 FUL

=>